Standout Papers

Improved survival in multiple myeloma and the impact of novel therapies 2002 2026 2010 2018 1.6k
  1. Improved survival in multiple myeloma and the impact of novel therapies (2007)
    Shaji Kumar, S. Vincent Rajkumar et al. Blood
  2. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma (2003)
    Robert A. Kyle, Morie A. Gertz et al. Mayo Clinic Proceedings
  3. Multiple Myeloma (2004)
    Robert A. Kyle, S. Vincent Rajkumar New England Journal of Medicine
  4. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance (2002)
    Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine
  5. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013)
    Shaji Kumar, Angela Dispenzieri et al. Leukemia
  6. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America (2007)
    Donna M. Weber, Christine Chen et al. New England Journal of Medicine
  7. Prevalence of Monoclonal Gammopathy of Undetermined Significance (2006)
    Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine
  8. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (2008)
    Robert A. Kyle, S. Vincent Rajkumar Leukemia
  9. Multiple myeloma (2017)
    Shaji Kumar, S. Vincent Rajkumar et al. Nature Reviews Disease Primers
  10. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study (2009)
    Ola Landgren, Robert A. Kyle et al. Blood
  11. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements (2012)
    Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology
  12. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial (2009)
    S. Vincent Rajkumar, Susanna Jacobus et al. The Lancet Oncology
  13. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group (2005)
    S. Vincent Rajkumar, Emily Blood et al. Journal of Clinical Oncology
  14. Multiple myeloma (2008)
    Robert A. Kyle, S. Vincent Rajkumar Blood
  15. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis (2004)
    Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology
  16. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial (2016)
    Brian G.M. Durie, Antje Hoering et al. The Lancet
  17. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma (2007)
    Robert A. Kyle, Ellen D. Remstein et al. New England Journal of Medicine
  18. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020)
    S. Vincent Rajkumar American Journal of Hematology
  19. Clonal competition with alternating dominance in multiple myeloma (2012)
    Jonathan J. Keats, Marta Chesi et al. Blood
  20. Multiple Myeloma: Diagnosis and Treatment (2016)
    S. Vincent Rajkumar, Shaji Kumar Mayo Clinic Proceedings
  21. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022)
    S. Vincent Rajkumar American Journal of Hematology
  22. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance (2018)
    Robert A. Kyle, Dirk R. Larson et al. New England Journal of Medicine
  23. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management (2024)
    S. Vincent Rajkumar American Journal of Hematology

Immediate Impact

8 by Nobel laureates 9 from Science/Nature 88 standout
Sub-graph 1 of 19

Citing Papers

Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy
2024 Standout
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
2022 Standout
4 intermediate papers

Works of S. Vincent Rajkumar being referenced

Multiple myeloma
2017 Standout
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
2007
and 13 more

Author Peers

Author Last Decade Papers Cites
S. Vincent Rajkumar 37605 32817 20954 885 52.1k
Angela Dispenzieri 24765 30738 15184 961 46.2k
Morie A. Gertz 20063 29428 13328 930 42.6k
Paul G. Richardson 31679 33345 22126 1.1k 50.7k
Bart Barlogie 30064 24023 18006 696 41.6k
Meletios Α. Dimopoulos 23206 20698 22523 1.7k 49.6k
Shaji Kumar 22717 22231 13685 1.0k 33.9k
Brian Druker 29898 17055 10862 597 54.0k
Philippe Moreau 18794 17218 13840 989 31.1k
Michael Andreeff 15751 25506 13420 987 47.2k
Nikhil C. Munshi 21055 24747 16361 790 39.2k

All Works

Loading papers...

Rankless by CCL
2026